KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Revenue data on record, last reported at $814.3 million in Q4 2025.

  • For Q4 2025, Revenue rose 11.47% year-over-year to $814.3 million; the TTM value through Dec 2025 reached $3.0 billion, up 8.05%, while the annual FY2025 figure was $3.0 billion, 8.05% up from the prior year.
  • Revenue reached $814.3 million in Q4 2025 per AMRX's latest filing, up from $784.5 million in the prior quarter.
  • Across five years, Revenue topped out at $814.3 million in Q4 2025 and bottomed at $493.1 million in Q1 2021.
  • Average Revenue over 5 years is $625.6 million, with a median of $613.4 million recorded in 2022.
  • Peak YoY movement for Revenue: fell 1.09% in 2021, then rose 18.4% in 2024.
  • A 5-year view of Revenue shows it stood at $536.9 million in 2021, then increased by 13.57% to $609.8 million in 2022, then increased by 1.18% to $617.0 million in 2023, then increased by 18.4% to $730.5 million in 2024, then rose by 11.47% to $814.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $814.3 million in Q4 2025, $784.5 million in Q3 2025, and $724.5 million in Q2 2025.